MYMD PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.84 USD | +1.07% |
|
+13.60% | -63.41% |
| 18/04 | MyMD Pharmaceuticals, Inc. Announces Resignation of Adam Kaplin as Chief Scientific Officer | CI |
| 09/04 | Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data | MT |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 13.17M 1.1B |
|---|---|---|---|---|---|
| Net income 2022 | -15M -1.25B | Net income 2023 | -4M -334M | EV / Sales 2022 | - |
| Net cash position 2022 | 4.69M 391M | Net cash position 2023 | 4.87M 406M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-2.94
x | P/E ratio 2023 |
-1.46
x | Employees | 6 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.68% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.07% | ||
| 1 week | +13.60% | ||
| Current month | +18.83% | ||
| 1 month | +18.83% | ||
| 3 months | -39.59% | ||
| 6 months | -75.73% | ||
| Current year | -63.41% |
1 week
2.53
2.93
1 month
2.003.50
Current year
2.008.70
1 year
2.0070.50
3 years
2.00298.50
5 years
2.00298.50
10 years
2.00298.50
| Managers | Title | Age | Since |
|---|---|---|---|
| President | 71 | 01/20/01 | |
Ian Rhodes
DFI | Director of Finance/CFO | 51 | 15/21/15 |
| Director/Board Member | 58 | 08/17/08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 58 | 08/17/08 | |
| President | 71 | 01/20/01 | |
Joshua Silverman
CHM | Chairman | 53 | 06/18/06 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 2.84 | +1.07% | 17,442 |
| 25/24/25 | 2.81 | -1.75% | 20,281 |
| 24/24/24 | 2.86 | +11.72% | 104,906 |
| 23/24/23 | 2.56 | -0.78% | 22,727 |
| 22/24/22 | 2.58 | +3.20% | 65,557 |
Delayed Quote Nasdaq, April 27, 2024 at 02:00 am IST
More quotes
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Companyâs MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Companyâs second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).
| 1st Jan change | Capi. | |
|---|---|---|
| -63.41% | 6.13M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- MYMD Stock
